Quoc Riccardo Bao

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Gaya Spolverato · 3 shared papers, 2023–2024 · strength 0.55
   • Paper Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review… DOI 10.1016/j.pan.2024.09.010↗
   • Paper Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. DOI 10.3390/cancers16234106↗
   • Paper Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.02.005↗
2. Isabella M. Frigerio · 3 shared papers, 2023–2024 · strength 0.55
   • Paper Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review… DOI 10.1016/j.pan.2024.09.010↗
   • Paper Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. DOI 10.3390/cancers16234106↗
   • Paper Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.02.005↗
3. Giovanni Butturini · 3 shared papers, 2023–2024 · strength 0.55
   • Paper Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review… DOI 10.1016/j.pan.2024.09.010↗
   • Paper Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. DOI 10.3390/cancers16234106↗
   • Paper Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.02.005↗
4. Atsushi Oba · 3 shared papers, 2020–2022 · strength 0.41
   • Paper Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Can… DOI 10.1093/bjs/znac002↗
   • Paper Neoadjuvant Treatment in Pancreatic Cancer. DOI 10.3389/fonc.2020.00245↗
   • Paper Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC. DOI 10.1177/1457496919900413↗
5. Marco Del Chiaro · 3 shared papers, 2020–2022 · strength 0.41
   • Paper Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Can… DOI 10.1093/bjs/znac002↗
   • Paper Neoadjuvant Treatment in Pancreatic Cancer. DOI 10.3389/fonc.2020.00245↗
   • Paper Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC. DOI 10.1177/1457496919900413↗
6. Richard David Schulick · 3 shared papers, 2020–2022 · strength 0.41
   • Paper Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Can… DOI 10.1093/bjs/znac002↗
   • Paper Neoadjuvant Treatment in Pancreatic Cancer. DOI 10.3389/fonc.2020.00245↗
   • Paper Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC. DOI 10.1177/1457496919900413↗
7. Marzia Tripepi · 2 shared papers, 2023–2024 · strength 0.36
   • Paper Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review… DOI 10.1016/j.pan.2024.09.010↗
   • Paper Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.02.005↗
8. Filippo Scopelliti · 2 shared papers, 2023–2024 · strength 0.35
   • Paper Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. DOI 10.3390/cancers16234106↗
   • Paper Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.02.005↗
9. Paolo Regi · 2 shared papers, 2023–2024 · strength 0.35
   • Paper Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. DOI 10.3390/cancers16234106↗
   • Paper Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.02.005↗
10. Alessandro Giardino · 2 shared papers, 2023–2024 · strength 0.35
    • Paper Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. DOI 10.3390/cancers16234106↗
    • Paper Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.02.005↗
11. Roberto Girelli · 2 shared papers, 2023–2024 · strength 0.35
    • Paper Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. DOI 10.3390/cancers16234106↗
    • Paper Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal aden… DOI 10.1016/j.pan.2023.02.005↗
12. Marco Ventin · 1 shared paper, 2024 · strength 0.20
    • Paper Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review… DOI 10.1016/j.pan.2024.09.010↗
13. Cristina Rosa Ferrone · 1 shared paper, 2024 · strength 0.20
    • Paper Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review… DOI 10.1016/j.pan.2024.09.010↗
14. Darío Gregori · 1 shared paper, 2024 · strength 0.19
    • Paper Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. DOI 10.3390/cancers16234106↗
15. Ana Gleisner · 1 shared paper, 2022 · strength 0.15
    • Paper Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Can… DOI 10.1093/bjs/znac002↗
16. Sana D. Karam · 1 shared paper, 2022 · strength 0.15
    • Paper Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Can… DOI 10.1093/bjs/znac002↗
17. Carlton C. Barnett · 1 shared paper, 2020 · strength 0.13
    • Paper Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC. DOI 10.1177/1457496919900413↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.